Trial Profile

Combination of Talimogene Laherparepvec With Atezolizumab in Patients With Residual Breast Cancer After Standard Neoadjuvant Multi-agent Chemotherapy (PROMETEO TRIAL)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Talimogene laherparepvec (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Pharmacogenomic; Therapeutic Use
Acronyms PROMETEO

Most Recent Events

27 Sep 2022 Planned End Date changed from 1 Nov 2023 to 27 Apr 2025.
01 Apr 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2022.
01 Apr 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com